Shamburg News · 8-K filed Nov 17, 2026, 8:57 AM EST
Nuo Therapeutics Reports Q3 2026 Revenue of $1.9 Million, Up 80%, and Provides Business Update
AURX · Nuo Therapeutics, Inc.
- Earnings
- Financial statements
- Materiality: high
Nuo Therapeutics reported total revenue of approximately $1.9 million for the third quarter ended September 30, 2026, up 80% from the prior-year period, and approximately $4.9 million for the first nine months, up 123%. The company reported a third-quarter net loss of $424,928, compared with $537,919 a year earlier, and basic and diluted loss per share of $0.01. Subsequent to quarter end, final funding of $325,000 was received under a loan agreement with total borrowings established at $2,000,000.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001437749-26-037320.
Written from the filing by Shamburg Markets. Figures are as reported by the company.